References

1. Bicocca VT, Phillips KG, Fisher DS, et al. Urinary comprehensive genomic profiling correlates urothelial carcinoma mutations with clinical risk and efficacy of intervention. J Clin Med. 2022;11(19):5827. doi: 10.3390/jcm11195827.
2. Salari K, Sundi D, Lee JJ, et al. Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk Submitted, 3/23
3. Lotan Y, Salari K, Feldman A, et al. Urinary comprehensive genomic profiling predicts urothelial cancer up to 12 years ahead of clinical diagnosis. An expanded analysis of the Golestan Cohort study. J Urol. 2023;209(suppl 4):e304. American Urological Society abstract MP22-19.
4. Salari K, Lee JJ, Bicocca VT, et al. Comprehensive genomic profiling of urine DNA for urothelial carcinoma detection and risk prediction. J Clin Oncol. 2022;40(suppl 6):450.